- Nectar Lifesciences
Nectar Lifesciences Limited Type Public Traded as BSE: 532649
Industry Pharmaceuticals Founded 1995 Headquarters Chandigarh, India Key people Sanjiv Goyal, Chairman and Managing Director, Dinesh Dua, CEO and Director, Aryan Goyal,Executive Director Products Cephalosporins, Revenue 11.2 billion Net income 1.02 billion Employees 2200 Website www.neclife.com
Nectar Lifesciences Limited (BSE: 532649, NSE: NECLIFE) is an integrated pharmaceutical company in India that manufactures high quality generic products for EU and USA. The company is the largest manufacturer of Cefuroxime Axetil API and Cefixime API in the world and manufactures 25% of menthol (raw) of the world.
The company is promoted by Goyal family and was incorporated in June 1995. The company went public in July 2005 with simultaneous listings on Bombay Stock Exchange and the National Stock Exchange of India. In 2010 New Silk Route PE invested INR 2.5 billion in the company.
The company's chairman and Managing Director is Mr Sanjiv Goyal.
Executive Director: Mr Aryan Goyal
CEO: Mr Dinesh Dua
The current market capitalization is about INR 9 billion (US$ 300 million).
Nectar Lifesciences manufactures oral and sterile active pharmaceutical ingredients, finished dosages and phytochemicals. The company is also in business of providing leading pharmaceutical organizations with contract research and manufacturing services. It also Manufactures Empty Hard Gelatin Capsules.
- Cefazolin Sodium
- Cefepime HCl
- Cefoperazone Sodium
- Cefotaxime Sodium
- Cefoxitin Sodium
- Cefpirome Sulphate
- Cefpodoxime Proxetil
- Ceftazidime Pentahydrate
- Ceftriaxone Sodium
- Cefuroxime Axetil
- Cefuroxime Sodium
- Cephalothin Sodium
- Cefditoren Pivoxil
Wikimedia Foundation. 2010.